Treatment with the leukotriene inhibitor montelukast for 10 days attenuates portal hypertension in rat liver cirrhosis

Hepatology

Volumn 51, Issue 6, 2010, Pages 2086-2096

  Steib, Christian J ^a   Bilzer, Manfred ^b   Op Den Winkel, Mark ^a   Pfeiler, Susanne ^c   Hartmann, Anna C ^a   Hennenberg, Martin ^a   Göke, Burkhard ^a   Gerbes, Alexander L ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Essex Pharma   (Germany)

^c InstClinChem   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; CYSTEINE; GADOLINIUM CHLORIDE; MONTELUKAST; THIOACETAMIDE; ZYMOSAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT LIGATION; CELL ACTIVATION; CONTROLLED STUDY; IN VIVO STUDY; KUPFFER CELL; LIVER CIRRHOSIS; MALE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RAT; SHAM PROCEDURE; TREATMENT DURATION;

ACETATES; ANIMALS; HYPERTENSION, PORTAL; KUPFFER CELLS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; LIGATION; LIVER; LIVER CIRRHOSIS; MALE; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES; THIOACETAMIDE; THROMBOXANE A2;

EID: 77952732092     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23596     Document Type: Article

References (39)

1. Shah V. Molecular mechanisms of increased intrahepatic resistance in portal hypertension. J Clin Gastroenterol 2007;41(10 Suppl 3): S259-S261. (Pubitemid 350059448)
2. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. HEPATOLOGY 2006;43(2 Suppl 1):S121-S131. (Pubitemid 43303976)
3. Graupera M, Garcia-Pagan JC, Abraldes JG, Peralta C, Bragulat M, Corominola H, et al. Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. HEPATOLOGY 2003;37:172-181. (Pubitemid 36042158)
4. Xu H, Korneszczuk K, Karaa A, Lin T, Clemens MG, Zhang JX. Thromboxane A2 from Kupffer cells contributes to the hyperresponsiveness of hepatic portal circulation to endothelin-1 in endotoxemic rats. Am J Physiol Gastrointest Liver Physiol 2005;288:G277-G283.
5. Steib CJ, Gerbes AL, Bystron M, Op dW, Hartl J, Roggel F, et al. Kupffer cell activation in normal and fibrotic livers increases portal pressure via thromboxane A(2). J Hepatol 2007;47:228-238. (Pubitemid 47021253)
6. Steib CJ, Gerbes AL. Signaling pathways in liver diseases: Kupffer cells. In: Dufour J-F, Clavien P-A, eds. Signaling Pathways in Liver Diseases. Heidelberg: Springer; 2009:69-79.
7. Graupera M, Garcia-Pagan JC, Titos E, Claria J, Massaguer A, Bosch J, et al. 5-Lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes. Gastroenterology 2002;122:387-393. (Pubitemid 34116990)
8. Titos E, Claria J, Bataller R, Bosch-Marce M, Gines P, Jimenez W, et al. Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. Gastroenterology 2000;119:794-805.
9. Shah V, Toruner M, Haddad F, Cadelina G, Papapetropoulos A, Choo K, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 1999;117:1222-1228. (Pubitemid 29512682)
10. Fiorucci S, Antonelli E, Mencarelli A, Orlandi S, Renga B, Rizzo G, et al. The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis. HEPATOLOGY 2005;42:539-548. (Pubitemid 41233646)
11. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. HEPATOLOGY 2002;35:478-491. (Pubitemid 34110432)
12. Wiest R, Groszmann RJ. Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin Liver Dis 1999;19:411-426. (Pubitemid 30032642)
13. Wiest R, Shah V, Sessa WC, Groszmann RJ. NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol 1999;276(4 Pt 1):G1043-G1051. (Pubitemid 29214119)
14. Zhou Q, Hennenberg M, Trebicka J, Jochem K, Leifeld L, Biecker E, et al. Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. Gut 2006;55:1296-1305. (Pubitemid 44277362)
15. Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. HEPATOLOGY 2007;46:242-253. (Pubitemid 47171941)
16. Trebicka J, Leifeld L, Hennenberg M, Biecker E, Eckhardt A, Fischer N, et al. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. HEPATOLOGY 2008;47:1264-1276. (Pubitemid 351547913)
17. Hennenberg M, Trebicka J, Stark C, Kohistani AZ, Heller J, Sauerbruch T. Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. Br J Pharmacol 2009;157:258-270.
18. Anegawa G, Kawanaka H, Yoshida D, Konishi K, Yamaguchi S, Kinjo N, et al. Defective endothelial nitric oxide synthase signaling is mediated by rho-kinase activation in rats with secondary biliary cirrhosis. HEPATOLOGY 2008;47:966-977. (Pubitemid 351449688)
19. Bernard B, Cadranel JF, Valla D, Escolano S, Jarlier V, Opolon P. Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology 1995;108:1828-1834.
20. Goulis J, Patch D, Burroughs AK. Bacterial infection in the pathogenesis of variceal bleeding. Lancet 1999;353:139-142. (Pubitemid 29088094)
21. Hou MC, Lin HC, Liu TT, Kuo BI, Lee FY, Chang FY, et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. HEPATOLOGY 2004;39:746-753.
22. Riccioni G, Bucciarelli T, Mancini B, Di Ilio C, D'Orazio N. Antileukotriene drugs: clinical application, effectiveness and safety. Curr Med Chem 2007;14:1966-1977. (Pubitemid 47209107)
23. Laleman W, Vander E, I, Zeegers M, Servaes R, Libbrecht L, Roskams T, et al. A stable model of cirrhotic portal hypertension in the rat: thioacetamide revisited. Eur J Clin Invest 2006;36:242-249.
24. Schauer RJ, Gerbes AL, Vonier D, Op dW, Fraunberger P, Bilzer M. Induction of cellular resistance against Kupffer cell-derived oxidant stress: a novel concept of hepatoprotection by ischemic preconditioning. HEPATOLOGY 2003;37:286-295.
25. Van de Casteele M, Hosli M, Sagesser H, Reichen J. Intraportal administration of glyceryl trinitrate or nitroprusside exerts more systemic than intrahepatic effects in anaesthetised cirrhotic rats. J Hepatol 1999;31:300-305. (Pubitemid 29349757)
26. Alabraba EB, Curbishley SM, Lai WK, Wigmore SJ, Adams DH, Afford SC. A new approach to isolation and culture of human Kupffer cells. J Immunol Methods 2007;326:139-144. (Pubitemid 47364734)
27. Bilzer M, Lauterburg BH. Peptidoleukotrienes increase the efflux of glutathione from perfused rat liver. Prostaglandins Leukot Essent Fatty Acids 1993;49:715-721. (Pubitemid 23278518)
28. Iwai M, Jungermann K. Leukotrienes increase glucose and lactate output and decrease flow in perfused rat liver. Biochem Biophys Res Commun 1988;151:283-290. (Pubitemid 18074165)
29. Garcia-Tsao G, Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004;18:353-372. (Pubitemid 38444136)
30. Neugebauer H, Hartmann P, Krenn S, Gluck T, Scholmerich J, Straub R, et al. Bacterial translocation increases phagocytic activity of polymorphonuclear leucocytes in portal hypertension: priming independent of liver cirrhosis. Liver Int 2008;28:1149-1157.
31. Wiest R, Chen F, Cadelina G, Groszmann RJ, Garcia-Tsao G. Effect of Lactobacillus-fermented diets on bacterial translocation and intestinal flora in experimental prehepatic portal hypertension. Dig Dis Sci 2003;48:1136-1141. (Pubitemid 36667839)
32. Krohn N, Kapoor S, Enami Y, Follenzi A, Bandi S, Joseph B, et al. Hepatocyte transplantation-induced liver inflammation is driven by cytokines-chemokines associated with neutrophils and Kupffer cells. Gastroenterology 2009;136:1806-1817.
33. Tejima K, Arai M, Ikeda H, Tomiya T, Yanase M, Inoue Y, et al. Ischemic preconditioning protects hepatocytes via reactive oxygen species derived from Kupffer cells in rats. Gastroenterology 2004;127:1488-1496. (Pubitemid 39457774)
34. Budick-Harmelin N, Dudas J, Demuth J, Madar Z, Ramadori G, Tirosh O. Triglycerides potentiate the inflammatory response in rat Kupffer cells. Antioxid Redox Signal 2008;10:2009-2022.
35. Ramadori G, Armbrust T. Cytokines in the liver. Eur J Gastroenterol Hepatol 2001;13:777-784.
36. Laleman W, Van Landeghem L, Severi T, Vander EI, Zeegers M, Bisschops R, et al. Both Ca2+ -dependent and -independent pathways are involved in rat hepatic stellate cell contraction and intrahepatic hyperresponsiveness to methoxamine. Am J Physiol Gastrointest Liver Physiol 2007;292:G556-G564.
37. Capra V, Ambrosio M, Riccioni G, Rovati GE. Cysteinyl-leukotriene receptor antagonists: present situation and future opportunities. Curr Med Chem 2006;13:3213-3226. (Pubitemid 44680865)
38. Muller D, Enderle GJ, Low O, Dietze E, Krell H. Bile ductular proliferation and altered leukotriene elimination in thioacetamide-induced fibrosis of rat liver. J Hepatol 1996;25:547-553. (Pubitemid 26345900)
39. Bisgaard H, Skoner D, Boza ML, Tozzi CA, Newcomb K, Reiss TF, et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulmonol 2009;44:568-579.